Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8
- Becker, H.
- Maharry, K.
- Mrózek, K.
- Volinia, S.
- Eisfeld, A.-K.
- Radmacher, M.D.
- Kohlschmidt, J.
- Metzeler, K.H.
- Schwind, S.
- Whitman, S.P.
- Mendler, J.H.
- Wu, Y.-Z.
- Nicolet, D.
- Paschka, P.
- Powell, B.L.
- Carter, T.H.
- Wetzler, M.
- Kolitz, J.E.
- Carroll, A.J.
- Baer, M.R.
- Caligiuri, M.A.
- Stone, R.M.
- Marcucci, G.
- Bloomfield, C.D.
Publication date
January 2014
DOI Publisher
Springer Science and Business Media LLC ISSN
0887-6924 Citation count (estimate)
12Abstract
Trisomy 8 (+8) is the most frequent numerical chromosome aberration in acute myeloid leukemia (AML), occurring in ~9% of adult patients.1 In one-third of such patients, +8 is the sole cytogenetic abnormality.1 These patients are mostly classified as having an intermediate prognosis.1, 2 The few available studies suggest that sole +8 AML is molecularly heterogeneous,3, 4, 5 but the clinical impact of mutations remains to be established. Moreover, although the biologic features of sole +8 AML have been investigated using genome-wide gene-6, 7 or microRNA-expression8 analyses, these studies included small numbers of patients
Add to ORKG